0001144204-10-068091.txt : 20110614 0001144204-10-068091.hdr.sgml : 20110614 20101223134837 ACCESSION NUMBER: 0001144204-10-068091 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20101223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVAVAX INC CENTRAL INDEX KEY: 0001000694 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222816046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 9920 BELWARD CAMPUS DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-268-2000 MAIL ADDRESS: STREET 1: 9920 BELWARD CAMPUS DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 CORRESP 1 filename1.htm

VIA EDGAR

December 23, 2010

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-7010

Attention:

Vanessa Robertson

Joel Parker

Jim Rosenberg

Re:	SEC Comment Letter dated December 21, 2010

Novavax, Inc.

Form 10-K for the year ended December 31, 2009

Filed on March 16, 2010

File No. 000-26770

Ladies and Gentlemen:

On behalf of Novavax, Inc. (the “Company”), this letter is to confirm receipt of the SEC Comment Letter dated December 21, 2010 and our telephone conversation this afternoon with Ms. Robertson of the staff of the Securities and Exchange Commission wherein we advised Ms. Robertson that our response to this letter would be provided by January 21, 2011.

Very truly yours,

/s/ Frederick W. Driscoll

Frederick W. Driscoll

Vice President & Chief Financial Officer